Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up.
Latest Information Update: 26 Jun 2023
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 08 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00196937).
- 08 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00196937).
- 08 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00196937).